Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
11.72
+0.52 (4.64%)
At close: Sep 17, 2026, 4:00 PM EDT
11.76
+0.04 (0.34%)
After-hours: Sep 17, 2026, 4:39 PM EDT
Kura Oncology Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Kura Oncology stock has a consensus rating of "Strong Buy" and an average price target of $32. The average 1-year stock price forecast is 173.04% higher than the current stock price, while the lowest is $15 (+27.99%) and the highest is $76 (+548.46%).
Price Target: $32 (+173.04%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kura Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 12 | 12 | 12 | 12 | 12 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Buy Reiterates $23 | Buy | Reiterates | $23 | +96.25% | Sep 10, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Maintains $12 | Buy | Maintains | $12 | +3.67% | Sep 10, 2026 |
| Barclays | Barclays | Buy Maintains $28 | Buy | Maintains | $28 | +138.91% | Sep 10, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $40 | Buy | Maintains | $40 | +241.30% | Sep 9, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $25 | Buy | Maintains | $25 | +113.31% | Aug 31, 2026 |
Financial Forecast
Revenue This Year
96.57M
from 67.48M
Increased by 43.11%
Revenue Next Year
212.18M
from 96.57M
Increased by 119.71%
EPS This Year
-3.16
from -3.18
EPS Next Year
-2.30
from -3.16
EPS and Forward PE are based on non-GAAP adjusted numbers.